To date, the MrI-based individualized prediction of psychosis has only been demonstrated in single-site studies. It remains unclear if MrI biomarkers generalize across different centers and Mr scanners and represent accurate surrogates of the risk for developing this devastating illness. Therefore, we assessed whether a MrI-based prediction system identified patients with a later disease transition among 73 clinically defined high-risk persons recruited at two different early recognition centers. Prognostic performance was measured using cross-validation, independent test validation, and Kaplan-Meier survival analysis. Transition outcomes were correctly predicted in 80% of test cases (sensitivity: 76%, specificity: 85%, positive likelihood ratio: 5.1). Thus, given a 54-month transition risk of 45% across both centers, MrI-based predictors provided a 36%-increase of prognostic certainty. After stratifying individuals into low-, intermediate-, and high-risk groups using the predictor's decision score, the high-vs low-risk groups had median psychosis-free survival times of 5 vs 51 months and transition rates of 88% vs 8%. The predictor's decision function involved gray matter volume alterations in prefrontal, perisylvian, and subcortical structures. Our results support the existence of a cross-center neuroanatomical signature of emerging psychosis enabling individualized risk staging across different high-risk populations. Supplementary results revealed that (1) potentially confounding between-site differences were effectively mitigated using statistical correction methods, and (2) the detection of the prodromal signature considerably depended on the available sample sizes. These observations pave the way for future multicenter studies, which may ultimately facilitate the neurobiological refinement of risk criteria and personalized preventive therapies based on individualized risk profiling tools.
Introduction
Two decades of early recognition research revealed that patterns of subtle prodromal symptoms allow persons with at-risk mental states (ARMS) for psychoses to be reliably identified using clinical high-risk criteria. Compared to the general population, these persons have a 100-fold higher risk for developing these devastating mental illnesses. However, relying solely on these symptoms leads to a correct 24-month disease prediction in only 29%
1 of cases and a 10-year transition likelihood between 35% 2 and 49%. 3 Therefore, tailoring preventive treatment to each individual's risk while minimizing harmful medication effects requires these rates to be considerably improved using valid and accessible prognostic markers.
An array of candidate biomarkers has been recently identified, suggesting that the ARMS is associated with alterations of neurocognitive performance 4 and brain abnormalities at the neuroanatomical, 5 functional, [6] [7] [8] and chemical 9, 10 levels. Overall, these alterations seem to be similar to, but less severe than those in the established disease. 11 More specifically, structural imaging studies comparing ARMS individuals with a subsequent full-blown illness (ARMS-T) to those without a later disease transition (ARMS-NT) showed reduced gray matter (GM) in prefrontal, temporal, cingulate, insular, and subcortical brain structures in the former vs the latter group. 12 However, most of these structural differences-albeit significant at the group level-have so far failed to produce clinically viable markers of the psychosis prodrome.
The gap between this research and its desired clinical application may originate from current study designs and univariate analysis methods: (1) vulnerability for reporting bias due to the small-sample problem inherent in monocentric high-risk research, 13 (2) decomposition of complex psychosis-related brain patterns into single voxels or clusters, 14 and hence (3) severe limitations in tracing these patterns in individuals as these univariate projections are quantified in terms of group-level statistical significance. Unfortunately, significance is largely useless for guiding the diagnostic process because a biomarker's applicability rather depends on its sensitivity and specificity, which measure its predictive performance at the single-subject level. 15 In contrast, multivariate pattern recognition methods, such as support vector machines (SVM), 16 have recently emerged as promising tools for the individualized diagnosis of various neuropsychiatric conditions 17, 18 based on their capacity to "learn" the innate interregional dependencies of distributed brain pathologies from training data and generalize the learned discriminative rules to new, unseen patients. 19 Thus, these methods may promote an objective way to increase prognostic certainty to levels required for individualized prevention, as shown by our previous work in two independent ARMS samples from Munich and Basel. 20, 21 Although these initial results support the utility of neuroimaging in predicting psychosis, tough replication and verification of these initial candidate markers is needed according to current biomarker development regulations. 22 A crucial validation step within this translational process is the demonstration of individualized disease prediction based on a single neuroanatomical signature evidenced across independent ARMS cohorts. The identification of such a cross-center signature is challenged by the clinical, neurobiological, and MRI-related heterogeneity of current small-sample ARMS cohorts. Hence, our previous findings potentially resulted from an accidentally good separability of our single-center study populations. 20, 21 This study is to our knowledge the first and to date largest study on the MRI-based cross-center prediction of psychosis. We hypothesized that the underlying biomarker would consist of a pattern of prefrontal, temporal, and subcortical brain alterations enabling the classification of true vs false prodromal individuals across independent ARMS populations. Furthermore, we expected the "neuroanatomical risk" computed from an ARMS person's loading on this signature to be closely related to their psychosis risk, as measured in terms of psychosis-free survival time.
Materials and Methods

Participants
We examined a pooled database of 73 ARMS individuals, who were previously enrolled into prospective, naturalistic studies conducted independently at the Early Recognition Services of the Department of Psychiatry and Psychotherapy ("Früherkennungs-und Therapiezentrum," FETZ), Ludwig-MaximilianUniversity, Munich, Germany, and the Department of Psychiatry ("Früherkennung von Psychosen," FePsy), University of Basel, Switzerland. Detailed study descriptions were given in earlier work. 21, 23 In summary, both sites employed clinical ultra-high-risk criteria closely corresponding to the well-established Personal Assessment and Crisis Evaluation (PACE) definitions. [15] [16] [17] At the FETZ, cognitive-perceptual basic symptoms additionally defined psychosis risk: 3 Hence, ARMS inclusion required (a) basic symptoms (FETZ), and/or (b) Attenuated Positive Symptoms (FETZ and FePsy), and/or (c) Brief Limited Intermittent Psychotic Symptoms (FETZ and FePsy) fulfilling specific time criteria, or (d) Decline in global functioning combined with risk-conferring traits as defined by each center's intake criteria (Supplementary Methods). Additionally, prodromal symptoms were assessed with the Brief Psychiatric Rating Scale (BPRS) and Scale for the Assessment of Negative Symptoms (SANS; Basel) and with the Positive and Negative Symptoms Scale (PANSS; Munich).
Exclusion criteria were age < 18 years, insufficient knowledge of German, IQ < 70, previously diagnosed psychotic disorders or transient psychotic episodes meeting transition criteria (see below), a diagnosed brain disease or substance dependency (except for cannabis in FePsy), previous head traumas, neurological, serious medical or surgical illnesses, or lifetime diagnoses of psychotic or borderline personality disorders as assessed by an experienced psychiatrist in detailed clinical interviews. Prior to study inclusion, only 4 out of 73 ARMS individuals had received low doses of atypical antipsychotics for behavioral control by the referring psychiatrist or general practitioner (3 participants olanzapine, 1 risperidone), all for less than 3 weeks. All subjects were regularly followed over 4 years and were offered supportive counseling and clinical management. At both centers, transition criteria were monitored monthly in the first year and quarterly thereafter using BPRS/PANSS severity thresholds closely corresponding to refs. 24, 25 : hallucinations scores ≥4 on the respective BPRS or PANSS item; OR scores ≥5 on the unusual though content or suspiciousness (BPRS)/delusions (PANSS) item, or on the conceptual disorganization item of either scale. Symptoms had to occur daily and persist for >1 week to be deemed a transition to frank psychosis. Using these criteria, the ARMS group was subdivided into 40 nontransitions (ARMS-NT) and 33 transitions (ARMS-T, transition rate: 45.2%; 95%-CI: 33.5%-56.9%). The mean (median; SD) follow-up period in the ARMS-NT group was 4.3 years (4.4; 1.5). In both centers, a diagnosis of first-episode psychosis was corroborated 1 year after transition using the 26 in Basel. Diagnostic criteria for schizophrenia/schizoaffective disorder were met by 22/5 transitions. OPRCRIT diagnoses were unavailable for 6 ARMS-T subjects, which could not be contacted. To build the MRI predictor, we selected 33 ARMS-NT individuals to match the ARMS-T group with respect to age, gender, and education years (table 1). The data of the remaining 7 subjects were used to further validate the MRI predictor after training and cross-validation.
All aspects of the study were reviewed and approved by the local ethics committees of both universities. Written informed consent was obtained from each participant before study inclusion.
MRI Data Acquisition and Preprocessing
MRI data acquisition and preprocessing were described in previous work 21, 27, 28 and are also detailed in the Supplementary Methods. All images were first carefully checked for MRI scanner artifacts and gross anatomical abnormalities by trained clinical neuroradiologists and then processed using the VBM8 toolbox (http:// dbm.neuro.uni-jena.de/vbm8/). This preprocessing produced modulated and normalized GM segments, which were smoothed with a 4 mm full-width-at-half-maximum Gaussian kernel prior to the subsequent analysis steps.
Multivariate Pattern Classification Analysis
We used our pattern recognition tool NeuroMiner to implement a fully automated machine learning pipeline, which (1) constructed sets of predictive neuroanatomical features from high-dimensional GM maps, and (2) learned decision rules from these features to predict psychosis at the single-subject level. To strictly separate the training process from the evaluation of the predictor's generalization capacity, the pipeline was completely embedded into a repeated, double cross-validation framework 29 (rdCV). As described previously, 27 rdCV computes an unbiased estimate of the method's expected diagnostic accuracy on new cases, rather than merely fitting the current study population. Furthermore, rdCV produces predictor ensembles that optimally separate single individuals from different groups, while avoiding overfitting to the peculiarities of the training data.
More specifically, the following analysis steps were wrapped into a Leave-One-Per-Group-Out cross-validation cycle at the outer (CV 2 ) and the inner (CV 1 ) cycles of rdCV: each training sample's GM tissue maps were initially corrected for center effects using partial correlation analysis and scaled voxel-wise to the range [0,1]. These maps entered a multivariate local linear learning algorithm 30 that weighted voxels according to the geometric distance ("margin") they conjointly induced between the ARMS-NT and ARMS-T classes. The algorithm's parameters were a priori set to σ = 2 and λ = 0.5 to extract sparse, nonredundant voxel sets from the data. To further reduce feature dimensionality, subsets of correlated voxels within the extracted patterns were projected to uncorrelated principal components (PC) using Robust Principal Component Analysis. 31 These PC features entered a linear ν-SVM algorithm (LIBSVM, (http:// www.csie.ntu.edu.tw/~cjlin/libsvm/) that determined the optimal between-group boundary by maximizing the margin between the neuroanatomically most similar subjects of opposite groups (the "support vectors"). 32 Optimal PC number and ν parameters were determined for each training sample within the inner rdCV cycle.
Finally, unseen CV 1 and CV 2 test subjects were processed by successively applying all training parameters to the test data: adjustment for center effects (partial correlations), voxel-wise scaling and weighting, dimensionality reduction, and linear kernel projection. Within kernel space, the SVM classifier determined a test subject's geometric position relative to the learned decision boundary, resulting in a decision value and a group membership prediction. This analysis sequence was repeated for each CV 1 training partition in a given CV 2 training fold, thus generating an ensemble classifier which computed a CV 2 test subject's group membership by averaging the decision scores of its SVM base learners (Supplementary Methods). Finally, for each subject, ensemble decisions were aggregated across those partitions, in which this subject had not been involved in the training process. Majority voting was used to determine the test subject's class probability, and thus its final out-of-training (OOT) group membership. Moreover, we applied the trained prediction system to the MRI data of the 7 ARMS-NT individuals, who were initially removed from the database. The predictive signature was visualized by computing the average voxel probability map across the entire rdCV structure as described in refs. 20, 27 (figure 1). Moreover, a parcellation analysis (table 3) measured the distribution of reliably predictive voxels across the 116 brain regions of the AAL template (Automated Anatomical Labeling). 33, 34 Two additional analyses were carried out using the same parameter setup as described above (Supplementary Results): In Supplementary Analysis 1 we quantified the strength of between-center effects comprising MRI and population-related differences, as well as the capacity of our correction method to mitigate these effects. Supplementary Analysis 2 measured how an ARMS-T sample size reduction in two-, four-, and six-out experiments affected OOT predictions and generalization to the independent test sample, extended by the left-out subjects.
Finally, a Kaplan-Meier survival analysis was performed in the entire ARMS population to assess the time dependency of transition with respect to neuroanatomical risk as defined by the subjects' decision scores. Therefore, the cohort's data analyses (chi-square tests were applied to sex, handedness, educational level, and individuals with a first-degree relative with schizophrenia. All other variables were evaluated using t tests, P significance). Furthermore, two-way analyses were carried out to evaluate possible center × group interaction effects (categorical data: chi-square tests, continuous data:
decision values were split into 33%-quantiles that assigned subjects to "low," "intermediate," and "high-risk" levels. Median survival times, transition rates, and recruitment center compositions were compared between risk levels using median and chi-square tests. Pairwise differences between survival functions were evaluated using log-rank tests. 1 . Voxel probability map of reliable contributions to the ARMS-NT vs ARMS-T decision boundary. Voxels with a probability of >50% were overlaid on the single subject Montreal Neurological Institute template using the MRIcron software package (http://www. sph.sc.edu/comd/rorden/mricron/). ARMS, at-risk mental states.
results
Sociodemographic and Clinical Findings
No significant center effects were found between the Basel and Munich samples regarding transition rates (Basel: 43.2%, Munich: 47.2%) and MRI-to-psychosis intervals (table 1) . Furthermore no center × group effects were found for age, sex, handedness, educational level, verbal IQ, family history of psychosis in first-degree relatives.
Within each center, ARMS-T and ARMS-NT groups did not differ in these parameters, as well as regarding prodromal and depressive symptoms (table 1) .
SVM Classification Analysis
In the pooled dataset (N = 66) the MRI predictor correctly classified ARMS-T and ARMS-NT individuals with an OOT accuracy of 80.3% (sensitivity = 75.8% / specificity = 84.8%, table 2). Only 1 of 7 independent ARMS-NT persons was wrongly labeled as ARMS-T (specificity = 85.7%, false positive rate = 14.3%). Thus, the generalization performance in the entire database (N = 73) attained a balanced accuracy of 80.4% (75.8% / 85%). Given a pretest disease probability of 45.2%, the positive / negative likelihood ratios of 5.1 / 0.29 indicate that an ARMS person with a positive / negative MRI finding would have an posttest probability of 81% / 19% for developing psychosis. The MRI predictor's diagnostic odds ratio in the entire database measured 17.7. Finally, the Kaplan-Meier analysis ( figure 2, table 3 ) detected a nonlinear accumulation of risk in the upper 33%-quantile of the neuroanatomical decision scores. This risk accumulation consisted of a nonlinear survival time decrease and transition rate increase from the low-to the high-risk groups: high-risk Note: The performance of the MRI prediction system was evaluated by means of sensitivity (Sens), specificity (Spec), balanced accuracy (BAC), false positive rate (FPR), positive / negative predictive value (PPV/NPV) as well as positive/negative likelihood and diagnostic odds ratio (LR+/LR−, DOR). These measures were calculated from the confusion matrix containing the number of true positives (TP), false negatives (FN), true negatives (TN), and false positives (FP). Furthermore, the posttest probability of developing psychosis (Post) after having a positive MRI testing was computed based on LR+ and the pretest probability (=transition rate).
ARMS had a transition rate of 87.5% and a median transition time of 147 days, whereas the respective values in the low-risk/intermediate-risk groups were 8.3%/37.5% and 1514 / 1456 days. Of the 8 (24.2%) misclassified ARMS-T subjects, 5 (63%)/3 (38%) were assigned to the intermediate-risk / low-risk groups. Risk groups did not significantly differ in their center composition (table 3) . The neuroanatomical decision function (figure 1) involved bilaterally reduced GM volume (−10%) in the prefrontal cortices of ARMS-T vs ARMS-NT subjects (table 4) , covering the dorsomedial, ventromedial, and orbitofrontal areas and extending to the cingulate and right intra-and perisylvian structures (inferior frontal gyrus, Rolandic operculum, insula, temporal pole). Further subcortical GM reductions were detected in the right basal ganglia (11.3%), the vermal lobule 10 and the cerebellar lobules 7b, 8, Crus 1 and 2 (table 4). In contrast, increased GM volume in ARMS-T was found in (1) most right-hemispheric perisylvian and temporal structures (supramarginal, inferior parietal, angular cortex), and (2) subcortical structures including the right pallidum, the vermal lobules 6-9 and the cerebellar lobules 4, 5, 6, 9, and 10.
Discussion
This is, to the best of our knowledge, the first multicenter study aiming at identifying a single neuroanatomical surrogate of the psychosis prodrome across two independent high-risk cohorts. Our study extends previous singlecenter investigations 20, 21, 27, 35 by pooling two independents high-risk cohorts recruited using different clinical highrisk criteria and examined by means of different MRI protocols. In summary, our main results suggest that the neuroanatomical signature of the prodrome may serve as an accurate biomarker to individually predict a high-risk person's clinical outcome in the early course of psychosis-in line with other neuropsychiatric conditions [36] [37] [38] [39] and irrespective of between-site differences. Our supplementary analyses indicate that these differences can be effectively attenuated using post hoc statistical correction methods (Supplementary Analysis 1) . Furthermore, we observed that prediction performance considerably depended on the available sample size (Supplementary Analysis 2), suggesting that the predictor's sensitivity and specificity will likely saturate in even larger training populations, as currently recruited across different international multicenter ARMS projects. Finally, we observed that this potential biomarker did not only predict a person's disease transition risk but also the time to transition. Both variables are of imminent importance for the staging of individual risk 40 and thus to the selection of optimal therapeutic interventions in the high-risk or prodromal phases of psychotic disorders. 41 
Neuroanatomy of Prodromal Psychosis
The visual analysis of the neuroanatomical predictor revealed GM volume reductions in ARMS-T vs ARMS-NT individuals covering prefrontal, cingulate, striatal, and cerebellar brain structures. Recent primate and large-scale human imaging studies suggest that these areas constitute prefronto-striato-cerebellar networks, which may subserve higher-order cognitive processes 42, 43 and hence may underlie executive, reward-related, and mnemonic deficits in prodromal and established psychosis. [44] [45] [46] [47] These findings overlap considerably with previous studies reporting GM volume reductions in the prefrontal, cingulate, perisylvian, and cerebellar cortices of genetic and clinical high-risk samples. 48 Furthermore, our results are in keeping with a series of neuroimaging studies that detected functional alterations of these networks in the ARMS, consisting of pathological associations between elevated striatal dopamine function and prefrontal activation during working memory and verbal fluency tasks.
10,48-50 These neurofunctional alterations seem to be Note: Medians of psychosis-free survival times/transition rates were compared using median/chi-square tests. Pairwise difference between survival curves were evaluated by means of log-rank test. Finally, possible center × risk group interactions were assessed using the chisquare statistic. Italicized values indicate significant findings at an alpha level of 0.05. associated with the course of the ARMS, including both remission 51 and clinical deterioration.
52,53
Interestingly, we also observed GM volume increments in ARMS-T vs ARMS-NT subjects, which showed a left temporal and inferior parietal distribution in line with findings reported by Borgwardt el al. 54 Given well-established progressive volume reductions in the temporo-parietal cortices of first-episode patients, 55 these intriguing relative GM volume increments in prodromal individuals have been interpreted in terms of a transient compensatory normalization of neural structure. 28, 54, 56 In this regard, the parallelism of volume decreases in the prefronto-striatocerebellar network and relative volume increases in the left temporo-parietal cortex may point to a nonlinear disease process driving these complex neuroanatomical changes as the prodrome evolves into full-blown psychosis. Our work adds to this hypothesis by revealing that the predictive signature of the psychosis prodrome is homogeneously expressed at the single-subject level. Further longitudinal MRI studies are needed to map the neuroanatomical disease course and hence to pinpoint the position of our cross-sectional "snapshot" along the psychosis trajectory.
Evidence-based Risk Stratification Using Neuroanatomical Biomarkers
Recent reviews on early intervention in the ARMS have suggested that preventive therapy may reduce transition rates and improve outcomes through a variety of therapeutic strategies. 57 These promising results may be mediated through a better neurobiological responsiveness in the earliest phases of psychosis. In this regard, the accurate quantification of risk for further disease progression is a central diagnostic requirement in order to implement stepped care strategies in early intervention services. 58 Stepped care naturally embraces the Hippocratic precept of primum nil nocere, which in the case of early intervention consists of avoiding harmful treatment, unnecessary distress, and stigmatization due to false positive diagnostic labeling. 41 In view of this precept, the established early recognition strategies identify persons at a 100-fold elevated risk of psychosis, 1 but this still does not allow deciding who necessitates intensive preventive efforts or, alternatively, who does not require any treatment at all. Thus, neurobiological and neurocognitive markers 4, 6 in combination with clinical data 59, 60 may ultimately enable the reliable single-subject quantification of risk across different early recognition centers. In turn, this progress will increase the safety and broader availability of early intervention. Our findings support the clinical applicability of such neurobiological markers in that we (1) detected a homogeneous neuroanatomical signature of emerging psychosis across independent high-risk cohorts and despite differing MRI data acquisition protocols, and (2) observed for the first time a close link between the ARMS persons' loadings on this MRI signature and their clinical risk level, as measured both in terms of transition likelihood and time to transition. Thus, given a baseline disease transition risk of 45% for an ARMS person over the next 4 years, a caregiver would have a 36%/26% higher prognostic certainty if this person receives a positive/negative MRI test result. Certainty would even further increase from 45% to 87% in a risk person having a MRI prediction score in the upper 33%-quantile. Hence, this prediction result would mark an imminent risk of disease transition, and as such a need for urgent preventive treatment. In contrast, for ARMS persons with an intermediate-to-low risk level a more conservative therapeutic approach would be indicated, which includes less harmful interventions like cognitive behavioral therapy to improve functioning, affective comorbidity 61 and prevent further deterioration, and regular reevaluations of the clinical and MRI status to monitor the development of risk markers over time. Importantly, for such evidence-based decision processes to operate in clinical reality, we will require an accurate biomarker that generalizes well to newly identified ARMS individuals, as suggested by our rigorous validation framework.
Challenges and Future Research Directions
Several challenges for future research efforts arise from our findings: First, the transition rate of 45% suggests a modestly higher (~10%) transition risk in our pooled population compared to other high-risk cohorts. 1 This increased risk may be caused by different pathways to care as our early recognition services are more linked with classical psychiatric institutions, whereas youth mental health services in Australia, the United States, or United Kingdom may enable persons to find professional help earlier and at lower thresholds. However, our ARMS cohort's transition risk was measured over an average follow-up period 3 Nevertheless, the generalization capacity of our candidate marker has to be further explored and validated in ARMS populations with a substantially lower risk of developing psychotic illness.
Second, the administration of the proposed MRI-based risk predictor requires the initial clinical exploration of a help-seeking person by specifically trained interviewers. This limits the broader availability of MRI-based risk prognostic tools across less specialized mental health services. A related issue in the present study is the use of checklists to assess the presence of prodromal symptoms (Supplementary Methods) followed by the application of BPRS/SANS and PANSS scales to evaluate symptom severity. As the initial clinical exploration represents an "upstream filter" to the MRI-based prognostic method, further prospective validation of our candidate marker is needed using current high-risk inventories. In this regard, the Schizophrenia Proneness Instrument, 62 the Structured Interview for Psychosis-Risk Syndromes, 63 or the Comprehensive Assessment of At-Risk Mental States 64 may provide more sensitive measures of prodromal symptomatology than scales developed for patients with established illness, and hence they may influence the performance of the downstream MRI predictor.
Third, profound between-center effects were detected that not only originated from scanner differences, but potentially also from heterogeneous ARMS inclusion criteria and a trend toward shorter transition intervals in the Munich sample. However, these supplementary data also suggest that such center effects can be effectively attenuated-as done in the present analysis-thus enabling the data pooling needed to create generalizable markers for the psychosis prodrome.
Finally, although our pattern recognition findings are based on a considerably larger ARMS sample compared to previous single-center studies, 20, 21, 27 it remains unclear whether these results will generalize to other ARMS cohorts examined using a wider variety of scanner variables (eg, different field strengths and MRI vendors). In this regard, our findings suggest that the performance of our candidate biomarker still lies on an ascending "learning curve," with the saturation point of its specificity and sensitivity to be reached at larger sample sizes, as recently shown for schizophrenia and Alzheimer's disease. 65, 66 The good crosscenter generalization capacity of MRI-based diagnostic tools demonstrated in these studies calls for the ultimate verification of our candidate marker in significantly larger samples, which will be provided by multicenter projects, like NAPLS 2, 67 EU-GEI, 68 PSYSCAN, and PRONIA (http:// pronia.eu) over the next years. As only such large-scale data facilitate the rigorous evaluation of the biomarkers' outof-center generalization capacity, they will allow to finally benchmarking the feasibility of MRI-enhanced early recognition and intervention in the psychosis prodrome.
Supplementary Material
Supplementary material is available at http://schizophreniabulletin.oxfordjournals.org.
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